openPR Logo
Press release

Cytology and HPV Testing Market is Expected to Grow to US$ 10.5 Billion by 2024

11-23-2017 09:04 AM CET | Health & Medicine

Press release from: TMR - Research Reports

Cytology and HPV Testing Market is Expected to Grow to US$ 10.5

The nature of the both the markets for cytology testing and HPV or human papillomavirus testing is oligopolistic in nature, states Transparency Market Research (TMR) in a research report. With the presence of only a handful of leading companies in the market, the competition is not that high as they compete among themselves with different or almost similar strategies. These few players are currently enjoying their reign in the global cytology and HPV testing market. The top three companies namely F.Hoffman-La Roche AG, Hologic, Inc., and Qiagen N.V., at present account for a Herculean share of 86% of the share in the global market HPV testing market and is likely to remain the same over the years ahead.

Read Report Overview @ https://www.transparencymarketresearch.com/cytology-hpv-testing-market.html

"Considering that the shares of the overall industry of the first and second place organizations obliging the demand for HPV testing are fairly close, up and coming endorsements for novel screening tests are probably going to significantly affect their position in the market," states a TMR analyst. For instance, the 2014 endorsement of Roche's cobas HPV test by the U.S. Food and Drug Administration (FDA) has brought about the upsurge of the organization's piece of the pie from what it was two or three years back. Likewise, Becton Dickinson and Hologic hold a collaborative share of around 89% in the cytology testing market at present. The companies in the overall HPV and cytology testing market are currently depending on collaborations and expansions for retaining their dominance over the market over the years ahead.

The global market for cytology and HPV testing is likely to rise at a CAGR of 2.9% from 2016 to 2024. In 2015, the market was worth US$7.9 bn and is likely to touch a valuation of US$10.5 bn by the end of 2024. In the market for cytology testing, the dominant segment is likely to be of cytology testing services and in the segment of HPV testing, the leader will be HPV testing services. These segments are likely to maintain their reign over the market over the years ahead. Region-wise, the market is likely to be led by North America expanding at a CAGR of 3.3% over the course of the forecast period.

The taking off frequency of HPV diseases and cervical cancer is likely to be credited to a few hazard factors, including the debilitating of the immune system because of ailment and a high number of sexual accomplices. Innovative progressions in healthcare and developing mindfulness among the people across the globe are likewise promising individuals to settle on high-precision demonstrative tests. Driven by these variables, the HPV testing market is relied upon to develop at a speedy rate over the years ahead. The growing significance of early diagnosis and detection options is also likely to play a key role in the growth of the market over the coming years.

Request Sample Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=2216

The developing frequency of cervical growth and also HPV diseases is the absolute most vital factor driving the interest for cytology and HPV testing. The quantity of new instances of cervical disease and rising number of deaths coming about because of this interminable condition have impelled patients to decide on early recognition and analysis techniques. The ascent in mindfulness about the business accessibility of screening tests has driven the reception of cytology testing. The high frequency rate of HPV contaminations and developing knowledge in regards to the risk that these diseases posture to the invulnerable framework have energized HPV testing and Pap spread screening.

About TMR

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Each TMR syndicated research report covers a different sector - such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.

US Office Contact

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Cytology and HPV Testing Market is Expected to Grow to US$ 10.5 Billion by 2024 here

News-ID: 829887 • Views: 200

More Releases from TMR - Research Reports

Pulmonary Drugs Market is Expected to Reach US$ 28,082.1 Million by the End of 2 …
According to the research report, the global pulmonary drugs market is expected to be worth US$ 28,082.1 mn by the end of 2024 as compared to US$ 48,039.7 mn in 2015. Analysts calculate that the global market will plummet at a CAGR of -6.3% during the forecast period of 2016 and 2024. The market will thrive as the demand for combination drugs is anticipated to remain on the rise during
North America Ventricular Assist Device Market is rising to a valuation of US$ 1 …
According to TMR, the opportunity in the North America market for VADs, which stood at US$0.4 bn in 2015, is likely to expand at a healthy CAGR of 9.20% between 2016 and 2024 and increase to US$1.07 bn by the end of the forecast period. The destination therapy (DT) segment has been reporting a greater application of VADs than the other two indication segments. It is expected to remain the
Dental Membrane and Bone Graft Substitutes Market to rise to US$ 922.6 Million b …
Transparency Market Research notes that innovation and expansion into emerging regions have served these companies well in strengthening their hold in the dental membrane and bone graft substitutes market. For instance, Switzerland-based Geistlich Pharma AG - a global manufacturer and supplier of dental products and devices - expanded its operations in Sydney, Australia and New Delhi, India in 2016. The global dental membrane and bone graft substitutes market is expected to
Human Vaccines Market is Estimated to Reach US$ 72.5 Billion by 2024
The global human vaccines market was valued at US$28.3 bn in 2015 and is estimated to reach US$72.5 bn by 2024, registering an 11.2% CAGR during the forecast period. By age group, pediatric vaccines accounted for a 57.5% share in the global human vaccines market in 2015. Adult vaccines, on the other hand, are expected to expand at a 13.2% CAGR from 2016 to 2024. Based on product, the pneumococcal segment

All 5 Releases


More Releases for HPV

HPV Vaccines Market Insights by Size, Status and Forecast 2024
Human Papillomaviruses (HPV) are members of papillomaviridae family a group of more than 150 related viruses. These are specifically known as papillomaviruses because of some of its types give rise to a wart or papilloma which are benign growths. Some of them are also associated with certain cancers and known as carcinogenic HPVs. More than 40 types of HPV viruses are easily transferred from one person to another by sexual
Cytology and HPV Testing Market - Research Analysis
The nature of the both the markets for cytology testing and HPV or human papillomavirus testing is oligopolistic in nature, states Transparency Market Research (TMR) in a research report. With the presence of only a handful of leading companies in the market, the competition is not that high as they compete among themselves with different or almost similar strategies. These few players are currently enjoying their reign in the global
Human Papillomavirus (HPV) Associated Cancer - Pipeline Review, H2 2017
"The Report Human Papillomavirus (HPV) Associated Cancer - Pipeline Review, H2 2017 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz" Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Human Papillomavirus (HPV) Associated Cancer - Pipeline Review, H2 2017, provides an overview of the Human Papillomavirus (HPV) Associated Cancer (Oncology) pipeline landscape. Human papillomavirus (HPV) is the most common viral infection
Cytology and HPV Testing Market: Disparate Levels of Awareness among Patients Re …
Over the years, the level of awareness among the global population regarding the various types of cancer has increased tremendously. The significance of early detection and diagnosis is not lost on them, resulting in the increased adoption of screening tests such as cytology and human papillomavirus (HPV) testing. The global market for cytology and HPV testing is presented with a host of sustained growth opportunities arising mainly from several emerging economies,
HPV Testing Market 2017- Qiagen, Roche Diagnostics, Hologic
HPV Testing Market 2017 Industry research report provides important information to identify and analyze the market need, market size and competition. This market research report used in maintaining competitiveness over competitors. “The human papillomavirus (HPV) test detects the presence of human papillomavirus, a virus that can lead to the development of genital warts, abnormal cervical cells or cervical cancer. The HPV testing is further classified into three sub-segments, namely, follow-up testing,
New Research: Global Human Papillomavirus (HPV) Market
MarketResearchReports.Biz presents this most up-to-date research on "Human Papillomavirus (HPV)- Epidemiology Forecast To 2023" Latest Report, Human Papillomavirus (HPV) - Epidemiology Forecast To 2023 provides an overview of the epidemiology trends of Human Papillomavirus (HPV) in seven major markets (US, France, Germany, Italy, Spain, UK and Japan). It includes 10 years epidemiology historical and forecasted data of Human Papillomavirus (HPV) prevalent or incident cases segmented by age, sex and subpopulations. The